1. Home
  2. KNF vs COGT Comparison

KNF vs COGT Comparison

Compare KNF & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Knife Riv Holding Co.

KNF

Knife Riv Holding Co.

HOLD

Current Price

$73.78

Market Cap

5.0B

Sector

N/A

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$32.37

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNF
COGT
Founded
1917
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
6.0B
IPO Year
2023
2018

Fundamental Metrics

Financial Performance
Metric
KNF
COGT
Price
$73.78
$32.37
Analyst Decision
Buy
Strong Buy
Analyst Count
8
15
Target Price
$97.25
$36.21
AVG Volume (30 Days)
507.2K
2.2M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,146,012,000.00
$7,871,000.00
Revenue This Year
$8.93
N/A
Revenue Next Year
$5.28
$1,733.58
P/E Ratio
N/A
N/A
Revenue Growth
8.52
N/A
52 Week Low
$58.72
$6.88
52 Week High
$95.29
$43.73

Technical Indicators

Market Signals
Indicator
KNF
COGT
Relative Strength Index (RSI) 42.02 44.77
Support Level $73.00 $30.87
Resistance Level $79.37 $37.69
Average True Range (ATR) 2.76 1.51
MACD -0.03 -0.08
Stochastic Oscillator 24.63 28.29

Price Performance

Historical Comparison
KNF
COGT

About KNF Knife Riv Holding Co.

Knife River Holding Co is an aggregates-led construction materials and contracting services provider. The segments of the company include West, Mountain, Central, and Energy Services. Each geographic segment offers a vertically integrated suite of products and services, including aggregates, ready-mix concrete, asphalt, and contracting services, while the Energy Services segment, which has locations throughout the company's geographic footprint, produces and supplies liquid asphalt and related services, for use in asphalt road construction, and is a supplier to some of the other segments.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: